The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

NCT06012448 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Dermal Hypersensitivity Reaction

Interventions

DRUG: Dupilumab

Sponsor

University of Michigan

Collaborators

[object Object]